Related Experiment Video

Updated: Jul 30, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K

PROTACs in the Management of Prostate Cancer

Poornachandra Yedla1, Ahmed O Babalghith2, Vindhya Vasini Andra3

  • 1Department of Pharmacogenomics, Institute of Translational Research, Asian Healthcare Foundation, Asian Institute of Gastroenterology Hospitals, Gachibowli, Hyderabad 500082, India.

Molecules (Basel, Switzerland)
|May 13, 2023
PubMed

Insights

Proteolysis-Targeting Chimeras (PROTACs) offer a novel approach to cancer therapy by degrading target proteins. This review explores PROTACs for prostate cancer, highlighting their advantages over traditional inhibitors.

Area of Science:

  • Oncology
  • Medicinal Chemistry
  • Molecular Biology

Background:

  • Targeted cancer therapies, including Proteolysis-Targeting Chimeras (PROTACs), are gaining traction due to reduced toxicity and enhanced selectivity.
  • PROTACs utilize the ubiquitin-proteasome system to degrade target proteins, offering a distinct mechanism from traditional inhibitors.
  • Prostate cancer (PC) presents challenges due to genetic alterations leading to drug resistance, necessitating innovative therapeutic strategies.

Purpose of the Study:

  • To provide an overview of PROTACs in prostate cancer treatment.
  • To discuss the advantages of PROTACs over conventional inhibitors for prostate cancer.
  • To explore the pathophysiology, structural design, and targeting strategies of PROTACs in prostate cancer.

Main Methods:

  • Review of existing literature on PROTACs and prostate cancer.
  • Analysis of PROTAC mechanism of action and design principles.
  • Discussion of specific targets and future prospects for PROTACs in prostate cancer.

Main Results:

  • PROTACs demonstrate a unique mechanism of action, enabling the degradation of previously undruggable proteins.
  • PROTACs show superiority over conventional inhibitors in targeting key proteins implicated in prostate cancer progression.
  • The development of PROTACs for prostate cancer, such as ARV-110, is advancing into clinical trials.

Conclusions:

  • PROTACs represent a promising therapeutic modality for prostate cancer, offering a novel approach to overcome drug resistance.
  • Further research into PROTAC structural design, linkerology, and target identification is crucial for optimizing their efficacy in prostate cancer.
  • PROTAC technology holds significant potential for the future of prostate cancer treatment.
Keywords:
PROTACandrogen receptormutationprostate cancerresistance

More Related Videos

Retzius-Sparing Robot-Assisted Radical Prostatectomy12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

7.8K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.2K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
228
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
215
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K